Europe

NICE has announced its recommendation of Bristol-Myers Squibb’s blockbuster immunotherapy drug Opdivo (nivolumab) for the treatment of two non-small cell lung cancer (NSCLC) indications in the second-line.

Concerns have grown that safety and efficacy standards might slip in the race to find a vaccine against the virus which has so far infected more than 29 million people and claimed over 926,000 lives globally.

When will there be a vaccine for Covid-19? That's one of the big questions we're all asking right now - and it's a big question for policymakers in Europe too.

For cancer patients, Every Day Counts… but significant differences exist in patient access to innovative oncology therapies in Europe. Accelerating time to patient access will be critical to beat cancer in Europe.

Les and Lynda Martin of Wicklow, Ireland, know first-hand how one gene therapy is delivering hope.

UK cost-effectiveness watchdog NICE has changed its stance on AstraZeneca’s Tagrisso as a first-line therapy for non-small cell lung cancer (NSCLC) after an improved “commercial arrangement” with the company.

Treatment with the drug within the NHS will only be funded if the bleed is in the gastrointestinal tract and the company provides the drug as per the terms of agreed commercial arrangement.

UK's NICE reverses original decision to reject lung cancer drug due to concerns over cost-effectiveness after manufacturer offers new commercial arrangement.

Projected spending for brand-name drugs in English primary care given US prices: a cross-sectional study.

The UK Government's ambitious mass coronavirus testing plans could cost as much as £100 billion, according to reports.

The agency expressed concerns on the limitations in the drug's cost-effectiveness model.

Switzerland’s Novartis and Roche were fined 444 million euros by France, after its competition authority said they used abusive practices to push costly eye injection Lucentis over a cheaper drug.

The cost-effectiveness estimates were higher than what is normally considered value for money for the NHS.

Essential Pharma is planning to discontinue production of first-line bipolar disorder treatment Priadel next year, leaving a range of more expensive alternatives on the market.

A final price will only be decided when the vaccine reaches its final testing stage.